Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab

  • Authors:
    • Rocco Giannicola
    • Graziella D'Arrigo
    • Cirino Botta
    • Rita Agostino
    • Pietro Del Medico
    • Antonia Consuelo Falzea
    • Vito Barbieri
    • Nicoletta Staropoli
    • Teresa Del Giudice
    • Pierpaolo Pastina
    • Valerio Nardone
    • Marika Monoriti
    • Graziella Calabrese
    • Giovanni Tripepi
    • Luigi Pirtoli
    • Pierfrancesco Tassone
    • Pierosandro Tagliaferri
    • Pierpaolo Correale
  • View Affiliations

  • Published online on: May 16, 2019     https://doi.org/10.3892/mco.2019.1859
  • Pages: 81-90
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immune‑checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor‑1, is an emerging treatment for metastatic non‑small cell lung cancer (mNSCLC). In order to prolong patient survival, this treatment requires a continuous cross‑priming of tumor derived‑antigens to supply fresh tumor‑specific immune‑effectors; a phenomenon that may also trigger auto‑immune‑related adverse events (irAEs). The present study therefore investigated the prognostic value of multiple autoimmunity‑associated parameters in patients with mNSCLC who were undergoing Nivolumab treatment. This retrospective study included 92 mNSCLC patients who received salvage therapy with Nivolumab (3 mg/kg, biweekly) between September 2015 and June 2018. Log‑rank test, Mantel‑Cox and McPherson analyses were conducted to correlate patient progression‑free survival (PFS) and overall survival (OS) with different parameters including blood cell counts, serum inflammatory markers and auto‑antibodies (AAbs). A median PFS and OS of 10 [inter‑quartile range (IQR): 5.8‑14.2] and 16 [IQR: 6.2‑25.8] months, respectively, were recorded, which did not correlated with age, histology or the number of previous chemotherapy lines. Male gender, the type of therapeutic regimens received prior to Nivolumab, and the occurrence of irAEs were revealed to be positive predictors of prolonged survival (P<0.05). Early detection (within 30 days) of >1AAbs among anti‑nuclear antigens (ANAs), extractable nuclear antigens (ENAs) and anti‑smooth cell antigens (ASMAs) correlated with prolonged PFS [hazard ratio (HR)=0.23; 95% confidence interval (CI): 0.08‑0.62; P=0.004] and OS [HR=0.28 (95% CI: 0.09‑0.88), P=0.03], with the type of treatment received prior to nivolumab (P=0.007) and with the risk of irAEs (P=0.002). In conclusion, increased serum levels of ANA, ENA and/or ASMA are consequential to Nivolumab administration and are predictive of a positive outcome in mNSCLC patients.

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Cetin K, Ettinger DS, Hei YJ and O'Malley CD: Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, epidemiology and end results program. Clin Epidemiol. 3:139–148. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Pilkington G, Boland A, Brown T, Oyee J, Bagust A and Dickson R: A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 70:359–367. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Noh JM, Kim JM, Ahn YC, Pyo H, Kim B, Oh D, Ju SG, Kim JS, Shin JS, Hong CS, et al: Effect of radiation therapy techniques on outcome in N3-positive IIIB non-small cell lung cancer treated with concurrent chemoradiotherapy. Cancer Res Treat. 48:106–114. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Bearz A, Berretta M and Tirelli U: Clinical effectiveness and cost-effectiveness of target therapies for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review. Curr Cancer Drug Targets. 18:405–409. 2018. View Article : Google Scholar : PubMed/NCBI

6 

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M and Di Costanzo F: Bevacizumab in non-small cell lung cancer. Drugs. 68:737–746. 2008. View Article : Google Scholar : PubMed/NCBI

8 

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Meyers DE, Bryan PM, Banerji S and Morris DG: Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol. 25:e324–e334. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Herzberg B, Campo MJ and Gainor JF: Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 22:81–88. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI

12 

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, et al: The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI

13 

Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, et al: Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol. 11:1511–1521. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, et al: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 33:853–861 e854. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Wang RF and Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev. 170:85–100. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, et al: Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 125:3981–3991. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Sanchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL, Sánchez-Arráez A, Sancho D and Melero I: Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 28 (Suppl 12):xii44–xii55. 2017. View Article : Google Scholar : PubMed/NCBI

18 

McDonnell AM, Robinson BW and Currie AJ: Tumor antigen cross-presentation and the dendritic cell: Where it all begins? Clin Dev Immunol. 2010:5395192010. View Article : Google Scholar : PubMed/NCBI

19 

Gebremeskel S and Johnston B: Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on clinical studies and considerations for combined therapies. Oncotarget. 6:41600–41619. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S and Morris ZS: Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. 17:995–1003. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M and Correale P: The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. Cell Death Dis. 7:e22992016. View Article : Google Scholar : PubMed/NCBI

22 

Wang D and DuBois RN: Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 36:1085–1093. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Kanterman J, Sade-Feldman M and Baniyash M: New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 22:307–318. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Wu J and Waxman DJ: Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett. 419:210–221. 2018. View Article : Google Scholar : PubMed/NCBI

25 

Shahabi V, Postow MA, Tuck D and Wolchok JD: Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 38:90–97. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Apetoh L, Ladoire S, Coukos G and Ghiringhelli F: Combining immunotherapy and anticancer agents: The right path to achieve cancer cure? Ann Oncol. 26:1813–1823. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Nardone V, Pastina P, Giannicola R, Agostino R, Croci S, Tini P, Pirtoli L, Giordano A, Tagliaferri P and Correale P: How to increase the efficacy of immunotherapy in NSCLC and HNSCC: Role of radiation therapy, chemotherapy, and other strategies. Front Immunol. 9:29412018. View Article : Google Scholar : PubMed/NCBI

28 

Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 23:6043–6053. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, et al: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol. 12:1005–1016. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M and Tagliaferri P: Immunotherapy of colorectal cancer: New perspectives after a long path. Immunotherapy. 8:1281–1292. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, et al: Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 14:4192–4199. 2008. View Article : Google Scholar : PubMed/NCBI

32 

Kudo-Saito C, Schlom J and Hodge JW: Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res. 11:2416–2426. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Hodge JW, Sharp HJ and Gameiro SR: Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm. 27:12–22. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Diem S, Keller F, Ruesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM and Flatz L: Pembrolizumab-triggered uveitis: An additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 39:379–382. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Wargo JA, Reuben A, Cooper ZA, Oh KS and Sullivan RJ: Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy. Semin Oncol. 42:601–616. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Gibney GT, Weiner LM and Atkins MB: Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI

37 

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al: iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017. View Article : Google Scholar : PubMed/NCBI

38 

Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, et al: Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. Oncoimmunology. 5:e11012052015. View Article : Google Scholar : PubMed/NCBI

39 

Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, et al: Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2:160252016. View Article : Google Scholar : PubMed/NCBI

40 

Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, et al: A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep. 16:133–140. 2006.PubMed/NCBI

41 

Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, et al: Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. J Thoracic Dis. 9:3123–3131. 2017. View Article : Google Scholar

42 

Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, et al: Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 12:112–118. 2011. View Article : Google Scholar : PubMed/NCBI

43 

Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, et al: Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 9:685–693. 2010. View Article : Google Scholar : PubMed/NCBI

44 

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, et al: Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget. 8:75904–75913. 2017. View Article : Google Scholar : PubMed/NCBI

45 

Day D and Hansen AR: Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 30:571–584. 2016. View Article : Google Scholar : PubMed/NCBI

46 

Weber JS, Yang JC, Atkins MB and Disis ML: Toxicities of immunotherapy for the practitioner. J Clin Oncol. 33:2092–2099. 2015. View Article : Google Scholar : PubMed/NCBI

47 

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, et al: Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer. 136:127–137. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, et al: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 108:16723–16728. 2011. View Article : Google Scholar : PubMed/NCBI

49 

Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, et al: Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol Immunother. 64:1159–1173. 2015. View Article : Google Scholar : PubMed/NCBI

50 

Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, et al: Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial. J Immunother. 37:26–35. 2014. View Article : Google Scholar : PubMed/NCBI

51 

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, et al: Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget. 9:20539–20554. 2018. View Article : Google Scholar : PubMed/NCBI

52 

Guirgis HM: The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. J Immunother Cancer. 6:152018. View Article : Google Scholar : PubMed/NCBI

53 

Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 23:8950–8958. 2005. View Article : Google Scholar : PubMed/NCBI

54 

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, et al: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 106:1–7. 2017. View Article : Google Scholar : PubMed/NCBI

55 

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A and Cortinovis DL: Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol. 129:27–39. 2018. View Article : Google Scholar : PubMed/NCBI

56 

Dudley JC, Lin MT, Le DT and Eshleman JR: Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 22:813–820. 2016. View Article : Google Scholar : PubMed/NCBI

57 

Zhu Y, Zhao F, Li Z and Yu J: Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 10:2475–2488. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A.C. ... Correale, P. (2019). Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab. Molecular and Clinical Oncology, 11, 81-90. https://doi.org/10.3892/mco.2019.1859
MLA
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A. C., Barbieri, V., Staropoli, N., Del Giudice, T., Pastina, P., Nardone, V., Monoriti, M., Calabrese, G., Tripepi, G., Pirtoli, L., Tassone, P., Tagliaferri, P., Correale, P."Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab". Molecular and Clinical Oncology 11.1 (2019): 81-90.
Chicago
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A. C., Barbieri, V., Staropoli, N., Del Giudice, T., Pastina, P., Nardone, V., Monoriti, M., Calabrese, G., Tripepi, G., Pirtoli, L., Tassone, P., Tagliaferri, P., Correale, P."Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab". Molecular and Clinical Oncology 11, no. 1 (2019): 81-90. https://doi.org/10.3892/mco.2019.1859